SpectronRx

The next chapter of radiopharmaceutical innovation will not be defined by science alone. It will be defined by the ability to develop, manufacture, and deliver at the pace the market now demands.

That is why SpectronRx is excited to attend the SNMMI 2026 Annual Meeting.

📍 Visit us at Booth 1023.

As more therapies advance toward commercialization, companies need partners capable of supporting far more than a single step in the process. From isotope production and analytical testing to contract development and GMP manufacturing, SpectronRx brings together the infrastructure and operational coordination required to help programs move forward with confidence. Built for the realities of Radiopharma, our facilities are designed to help innovators reduce complexity, accelerate ex*****on, and prepare for long-term scale.

We look forward to connecting with partners, customers, and industry leaders shaping the future of nuclear medicine and precision medicine in Los Angeles.

ICYMI: Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx in support of late-stage clinical manufacturing for Rhenium-186 and REYOBIQ.

We’re proud to support this important program as an additional GMP manufacturing site and look forward to what’s ahead.

👉 Check out today’s Contract Pharma for more: https://www.contractpharma.com/breaking-news/plus-therapeutics-initiates-manufacturing-activities-tech-transfer-with-spectronrx/

In a time-sensitive, decay-driven environment, access changes everything.

✔️ 21+ isotopes.
✔️ One integrated platform.
✔️ Endless possibilities.

From Ac-225 and Pb-212 to Cu-64, Ga-68, and Lu-177, SpectronRx supports the full spectrum of radiopharmaceutical development and manufacturing, helping partners move with speed, scale, and confidence.

👉 Learn more: SpectronRx.com

Congratulations to the team at Telix Pharmaceuticals on dosing the first patient in the Phase III IPAX BrIGHT trial evaluating TLX101-Tx for recurrent glioblastoma.

This milestone marks an important step forward in addressing one of the most challenging cancers, where new therapeutic approaches are urgently needed. The study’s combination of targeted radiopharmaceutical therapy with established chemotherapy highlights the growing momentum behind precision medicine in oncology.

It is also encouraging to see the integration of diagnostic and therapeutic capabilities, with TLX101-Px (Pixclara) supporting both patient selection and response assessment. This kind of end-to-end approach reflects where the field is headed.

👉 Read more here: https://www.auntminnie.com/clinical-news/molecular-imaging/nuclear-medicine/news/15822312/telix-doses-first-patient-in-glioblastoma-trial